CardioTech Announces Fiscal Third Quarter 2007 Conference Call on February 15 at 2:30 PM Eastern
Share:
WILMINGTON, Mass., Feb. 6: CardioTech International, Inc. (AMEX:CTE), a developer and manufacturer of advanced materials and medical devices for the treatment of cardiovascular and other diseases, announced today that it will release its fiscal third quarter 2007 financial results before the market opens on Thursday, February 15, 2007. Following the release, the Company will host a conference call for investors at 2:30 p.m. ET (11:30 a.m. PT) to discuss its fiscal third quarter results.
Participants should dial-in (866) 256-9239, Conference ID# 1028590 or (703) 639-1213 outside the U.S. Please dial-in 10 minutes before the call is scheduled to begin. A replay of the call will be available through March 7. Access information will appear on the press release and the Company's website.
MDM West Conference & Exposition
CardioTech also announced today that the first integrated marketing initiative for its polymer development and manufacturing division and its OEM manufacturing division will be launched at the Medical Design & Manufacturing (MDM West) exposition that will take place February 13-15 at the Anaheim Convention Center in California. MDM West Conference & Exposition attendees are interested in collaborative outsourcing and provider partnerships for a wide range of disease categories. Through its vertical integration effort, CardioTech is seeking to expand its services to existing customers and attract new ones to its strong products and services offerings in biomaterials development and medical device engineering and manufacturing.
About CardioTech International:
CardioTech International, Inc. is a medical device company that designs, develops, manufactures and sells innovative material and products for the treatment of cardiovascular, orthopedic, oncology and other diseases. The Company's strategic goal is to incorporate its proprietary polymer technology into a wide range of breakthrough medical applications. CardioPass(TM) is CardioTech's proprietary, synthetic coronary artery bypass graft. (SynCAB) The Company generates revenues from sales of advanced medical devices and materials, as well as from contracted product design and development services.
More information about CardioTech is available at its website: http://www.cardiotech-inc.com/.
For Further Information Contact:
Eric Walters
Vice President & Chief Financial Officer
CardioTech International, Inc.
978-657-0075
general-info@cardiotech-inc.com
Sylvia Dresner
Senior Vice President
VMW Corporate & Investor Relations
212-616-6161
info@vmwcom.com
Source: CardioTech International, Inc.
CONTACT: Eric Walters, Vice President &Chief Financial Officer of CardioTech International, Inc. +1-978-657-0075, general-info@cardiotech-inc.com; or Sylvia Dresner, Senior Vice President of VMW Corporate & Investor Relations, +1-212-616-6161, info@vmwcom.com
Web site: http://www.cardiotech-inc.com/
